Burkina FasoTuberculosis profile
Population  2014 18 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (1.2–2.1) 9.1 (6.6–12)
Mortality (HIV+TB only) 0.47 (0.39–0.56) 2.7 (2.2–3.2)
Prevalence  (includes HIV+TB) 14 (7.6–23) 81 (43–130)
Incidence  (includes HIV+TB) 9.4 (8.5–10) 54 (48–59)
Incidence (HIV+TB only) 1.2 (1–1.3) 6.6 (5.7–7.4)
         
Case detection, all forms (%) 59 (53–65)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
77 (14–140) 98 (25–170)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 722   217
Pulmonary, clinically diagnosed 815   109
Extrapulmonary 683   0
       
Total new and relapse 5 546    
Previously treated, excluding relapses 246    
Total cases notified 5 792    
Among 3 722 new cases:
55 (1%) cases aged under 15 years; male:female ratio: 2.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 6 (<1%) 273 (48%) 285
Laboratory-confirmed RR-/MDR-TB cases     53
Patients started on MDR-TB treatment ***     34
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 553 (96)
HIV-positive TB patients 656 (12)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 641 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 564 (86)
HIV-positive people screened for TB 64 503  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (80) 5 125
Previously treated cases registered in 2013 (75) 400
HIV-positive TB cases, all types, registered in 2013 (71) 680
RR-/MDR-TB cases started on second-line treatment in 2012 (58) 26
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 9.6
% Funded domestically 2%
% Funded internationally 21%
% Unfunded 77%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-25 Data: www.who.int/tb/data